UroGen Pharma Ltd. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 32/100
What the filing says
UroGen entered into a supply agreement with TAPI NL B.V. (Netherlands) effective January 1, 2026, for active pharmaceutical ingredients with a 10-year initial term post-launch, followed by automatic 2-year renewals. Specific pricing, volumes, and purchase commitments are redacted ([***]). A second amendment to an existing License and Supply Agreement with Medac (Germany, effective January 2024) was signed January 15–18, 2026, adding Exhibit D to define long-term storage activities for validation batches; no financial terms disclosed.
Why this rating
Supply agreements are operationally important but terms (pricing, volumes, %) redacted; no disclosed dollar amounts or share counts. Routine supplier relationship maintenance; not material relative to $620M market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.